Patents by Inventor Tomoyuki Igawa
Tomoyuki Igawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11820793Abstract: The present inventors discovered that by forming a large immune complex comprising antigens containing two or more antigenic binding units (epitopes) and two or more antigen-binding molecules (for example, antibodies), elimination from the plasma of the antigens containing two or more antigenic binding units can be accelerated. Moreover, they found that by using this characteristic and by further using antigen-binding molecules having an ion-dependent antigen-binding activity, elimination of the antigens can further be accelerated and the above problem can be solved.Type: GrantFiled: August 22, 2018Date of Patent: November 21, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Naoka Hironiwa
-
Publication number: 20230322898Abstract: The present invention provides a pharmaceutical composition comprising cells expressing a chimeric receptor, for use in combination with administration of an antigen-binding molecule, wherein the chimeric receptor comprises an extracellular domain, the extracellular domain comprises an extracellular domain of an immunoreceptor, an extracellular domain variant of an immunoreceptor, or a portion thereof, and the antigen-binding molecule is a multispecific antigen-binding molecule having a target antigen recognition site and an immunoreceptor recognition site which recognizes the immunoreceptor.Type: ApplicationFiled: July 30, 2021Publication date: October 12, 2023Applicants: Chugai Seiyaku Kabushiki Kaisha, Yamaguchi UniversityInventors: Tomoyuki Igawa, Mika Sakurai, Takashi Suzuki, Kanako Tatsumi, Shun Shimizu, Koji Tamada, Yukimi Sakoda
-
Publication number: 20230279099Abstract: The present inventors discovered that problems of existing antibody pharmaceuticals can be solved by producing antigen-binding molecules that contain an antigen-binding domain whose antigen-binding activity varies depending on the concentration of a target tissue-specific compound. Use of antigen-binding molecules of the present invention enables various diseases that originate from a target tissue to be treated in a manner specific to the target tissue.Type: ApplicationFiled: April 25, 2023Publication date: September 7, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shigero Tamba, Kanako Tatsumi, Shun Shimizu, Shojiro Kadono
-
Publication number: 20230277442Abstract: The present inventors discovered that a significant stabilization effect was achieved by using an acidic amino acid, aspartic acid or glutamic acid as a counter ion species in histidine buffer or tris(hydroxymethyl)aminomethane, specifically by using histidine-aspartate buffer or histidine-glutamate buffer, or tris(hydroxymethyl)aminomethane-aspartate or tris(hydroxy-methyl) aminomethane-glutamate as a buffer. The present inventors also discovered that a significant stabilization effect was achieved by using an acidic amino acid, aspartic acid or glutamic acid, as a counter ion species to a basic amino acid such as arginine, specifically by using arginine-aspartate or arginine-glutamate.Type: ApplicationFiled: February 24, 2023Publication date: September 7, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki IGAWA, Chifumi MORIYAMA
-
Patent number: 11739149Abstract: The present inventors have successfully prepared an antigen-binding molecule comprising an antibody variable region that has binding activity against a molecule expressed on the surface of a T cell and a molecule expressed on the surface of any other immunocyte, but does not bind to these molecules at the same time. The present invention allows the preparation of an antigen-binding molecule capable of circumventing adverse reactions that may be caused by the cross-linking of T cells to other immunocytes, and provides an antigen-binding molecule suitable as a drug.Type: GrantFiled: December 5, 2019Date of Patent: August 29, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shojiro Kadono, Naoka Hironiwa, Mika Sakurai
-
Publication number: 20230265176Abstract: The present disclosure provides an antigen-binding molecule that comprises an antigen-binding moiety which specifically binds to an antigen and an Fc polypeptide comprising a first and second Fc region variants, with the first Fc region variant being fused to the antigen-binding moiety but the second Fc region variant being not fused to the antigen-binding moiety or to any other antigen-binding moieties which bind to the antigen, the antigen-binding molecule having a substantially decreased Fc gamma receptor-binding activity and having a maintained or increased C1q-binding activity when compared to an antigen binding molecule comprising the parent Fc region. The antigen-binding molecule of this format can enhance the clearance of the virus of interest while reducing the risk of ADE.Type: ApplicationFiled: August 13, 2021Publication date: August 24, 2023Inventor: Tomoyuki IGAWA
-
Publication number: 20230257470Abstract: The present invention demonstrated that the modification of the Fc region of an antigen-binding molecule into an Fc region that does not form in a neutral pH range a heterotetramer complex containing two molecules of FcRn and an active Fc? receptor improved the pharmacokinetics of the antigen-binding molecule and reduced the immune response to the antigen-binding molecule. The present invention also revealed methods for producing antigen-binding molecules having the properties described above, and successfully demonstrated that pharmaceutical compositions containing as an active ingredient such an antigen-binding molecule or an antigen-binding molecule produced by a production method of the present invention have excellent features over conventional antigen-binding molecules in that when administered, they exhibit improved pharmacokinetics and reduced in vivo immune response.Type: ApplicationFiled: April 11, 2023Publication date: August 17, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Atsuhiko Maeda, Kenta Haraya, Yuki Iwayanagi, Tatsuhiko Tachibana, Futa Mimoto, Taichi Kuramochi, Hitoshi Katada, Shojiro Kadono
-
Patent number: 11718678Abstract: The present invention demonstrated that the modification of the Fc region of an antigen-binding molecule into an Fc region that does not form in a neutral pH range a heterotetramer complex containing two molecules of FcRn and an active Fc? receptor improved the pharmacokinetics of the antigen-binding molecule and reduced the immune response to the antigen-binding molecule. The present invention also revealed methods for producing antigen-binding molecules having the properties described above, and successfully demonstrated that pharmaceutical compositions containing as an active ingredient such an antigen-binding molecule or an antigen-binding molecule produced by a production method of the present invention have excellent features over conventional antigen-binding molecules in that when administered, they exhibit improved pharmacokinetics and reduced in vivo immune response.Type: GrantFiled: March 2, 2020Date of Patent: August 8, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Atsuhiko Maeda, Kenta Haraya, Yuki Iwayanagi, Tatsuhiko Tachibana, Futa Mimoto, Taichi Kuramochi, Hitoshi Katada, Shojiro Kadono
-
Patent number: 11718672Abstract: The disclosure provides multispecific antigen-binding molecules that comprise a first antigen-binding moiety and a second antigen-binding moiety, each of which is capable of binding to CD3 and CD137, but does not bind to CD3 and CD137 at the same time; and a third antigen-binding moiety that is capable of binding to DLL3, preferably human DLL3, which induce T-cell dependent cytotoxity more efficiently whilst circumventing adverse toxicity concerns or side effects that other multispecific antigen-binding molecules may have. The present invention provides multispecific antigen-binding molecules and pharmaceutical compositions that can treat various cancers, especially those associated with DLL3, by comprising the antigen-binding molecule as an active ingredient.Type: GrantFiled: February 14, 2022Date of Patent: August 8, 2023Assignee: Chugai Seiyaki Kabushiki KaishaInventors: Sotaro Naoi, Shu Feng, Tomoyuki Igawa, Shu Wen Samantha Ho
-
Publication number: 20230227498Abstract: The present invention provides efficient methods based on alteration of the protein A-binding ability, for producing or purifying multispecific antibodies having the activity of binding to two or more types of antigens to high purity through a protein A-based purification step alone. The methods of the present invention for producing or purifying multispecific antibodies which feature altering amino acid residues of antibody heavy chain constant region and/or variable region. Multispecific antibodies with an altered protein A-binding ability, which exhibit plasma retention comparable or longer than that of human IgG1, can be efficiently prepared in high purity by introducing amino acid alterations of the present invention into antibodies.Type: ApplicationFiled: March 31, 2023Publication date: July 20, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuya Wakabayashi, Eriko Ito
-
Publication number: 20230220083Abstract: An objective of the present invention is to provide methods for facilitating antigen-binding molecule-mediated antigen uptake into cells, methods for facilitating the reduction of antigen concentration in plasma, methods for increasing the number of antigens to which a single antigen-binding molecule can bind, methods for improving pharmacokinetics of antigen-binding molecules, antigen-binding molecules improved for facilitated antigen uptake into cells, antigen-binding molecules capable of facilitating the reduction of antigen concentration in plasma, antigen-binding molecules capable of repeatedly binding to antigens, antigen-binding molecules with improved pharmacokinetics, pharmaceutical compositions comprising such an antigen-binding molecule, and methods for producing those described above.Type: ApplicationFiled: November 3, 2022Publication date: July 13, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki IGAWA, Shinya ISHII, Atsuhiko MAEDA, Takashi NAKAI
-
Publication number: 20230212315Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.Type: ApplicationFiled: December 15, 2022Publication date: July 6, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuo Kojima, Tetsuhiro Soeda, Atsushi Muto, Takehisa Kitazawa, Yukiko Nishida, Chifumi Imai, Tsukasa Suzuki, Kazutaka Yoshihashi
-
Publication number: 20230210991Abstract: In one non-limiting embodiment, the present disclosure is an antibody-containing formulation comprising an anti-IL-6 receptor antibody as an active ingredient, and contains histidine-aspartate buffer or histidine-glutamate buffer, Poloxamer 188, and arginine, and has a pH of 5.5 to 6.6. In one non-limiting embodiment, the present disclosure is a method of stabilizing an antibody-containing solution, a method of suppressing antibody association (e.g., dimerization), and a method of suppressing the generation of insoluble particles, wherein L-aspartic acid or L-glutamic acid, and optionally, Poloxamer 188 are added.Type: ApplicationFiled: May 28, 2021Publication date: July 6, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Daisuke Kameoka, Masaya Yasutake, Masakazu Fukuda, Atsushi Watanabe, Tomoyuki Igawa, Chifumi Imai, Akira Hayasaka
-
Publication number: 20230203144Abstract: The present invention provides a combination of two or more isolated or purified anti-C5 antibodies, wherein the isolated or purified anti-C5 antibodies bind to an epitope within the beta chain or alpha chain of C5 and wherein the isolated or purified anti-C5 antibodies to be combined do not compete with each other for binding to the epitope. Methods of using the combination for treating an individual having a complement-mediated disease or condition which involves excessive or uncontrolled activation of C5, or for enhancing the clearance of C5 from plasma in an individual, are also provided.Type: ApplicationFiled: November 29, 2022Publication date: June 29, 2023Inventors: Eriko MURATA, Shinya ISHII, Tomoyuki IGAWA, Yuji HORI, Norihito SHIBAHARA
-
Publication number: 20230203108Abstract: The present invention relates to granzyme B variants with increased protease activities and/or increased resistance against inhibitors; polynucleotides encoding the granzyme B variants; cells expressing the granzyme B variants; pharmaceutical compositions containing cells expressing the granzyme B variants; and pharmaceutical compositions containing the granzyme B variants. In some embodiments, the pharmaceutical compositions may be used in combination with cells expressing chimera receptors and/or antigen-binding molecules.Type: ApplicationFiled: May 28, 2021Publication date: June 29, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Yasunori Komori, Tomoyuki Igawa, Atsushi Narita, Shinya Ishii
-
Publication number: 20230183363Abstract: The present inventors successfully obtained anti-NR10 antibodies having an effective neutralizing activity against NR10. The anti-NR10 antibodies provided by the present invention are useful as, for example, pharmaceuticals for treating or preventing inflammatory diseases.Type: ApplicationFiled: October 28, 2022Publication date: June 15, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Taichi Kuramochi, Keiko Kasutani, Souhei Ohyama, Hiroyuki Tsunoda, Tomoyuki Igawa, Tatsuhiko Tachibana, Hirotake Shiraiwa, Keiko Esaki
-
Patent number: 11673947Abstract: The present inventors discovered that problems of existing antibody pharmaceuticals can be solved by producing antigen-binding molecules that contain an antigen-binding domain whose antigen-binding activity varies depending on the concentration of a target tissue-specific compound. Use of antigen-binding molecules of the present invention enables various diseases that originate from a target tissue to be treated in a manner specific to the target tissue.Type: GrantFiled: August 13, 2019Date of Patent: June 13, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shigero Tamba, Kanako Tatsumi, Shun Shimizu, Shojiro Kadono
-
Publication number: 20230174655Abstract: An objective of the present invention is to provide a polypeptide containing an Fc region having maintained or decreased binding activities towards both allotypes of Fc?RIIa, types H and R, and having enhanced Fc?RIIb-binding activity in comparison with a parent polypeptide; a pharmaceutical composition containing the polypeptide; an agent for treating or preventing immunological inflammatory diseases that includes the pharmaceutical composition; a production method thereof; and a method for maintaining or decreasing binding activities towards both allotypes of Fc?RIIa and enhancing the Fc?RIIb-binding activity. Specifically, it is found that a polypeptide containing an antibody Fc region that has an alteration of substituting Pro at position 238 (EU numbering) with Asp or Leu at position 328 (EU numbering) with Glu enhances Fc?RIIb-binding activity, and maintains or decreases binding activities towards both allotypes of Fc?RIIa, types H and R.Type: ApplicationFiled: June 22, 2022Publication date: June 8, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Futa Mimoto, Taichi Kuramochi, Tomoyuki Igawa, Hitoshi Katada, Shojiro Kadono
-
Publication number: 20230159648Abstract: The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.Type: ApplicationFiled: January 12, 2023Publication date: May 25, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shinya Ishii, Atsuhiko Maeda, Mika Sakurai, Tetsuo Kojima, Tatsuhiko Tachibana, Hirotake Shiraiwa, Hiroyuki Tsunoda, Yoshinobu Higuchi
-
Publication number: 20230151112Abstract: It was discovered that the use of an antigen-binding molecule having a cancer-specific antigen-binding domain, and a TNF superfamily-binding domain or a TNF receptor superfamily-binding domain enables agonist activity against a factor belonging to the TNF superfamily or the TNF receptor superfamily to be exhibited only in the presence of cancer-specific antigen-expressing cells, thus leading to activation of immune cells and thereby maintain anti-tumor activity while avoiding side effects such as hepatotoxicity. It was also discovered that concomitant use of the antigen-binding molecule with an antigen-binding molecule having a cancer-specific antigen-binding domain and a T cell receptor complex-binding domain can avoid side effects while increasing the anti-tumor activity.Type: ApplicationFiled: September 21, 2022Publication date: May 18, 2023Inventors: Tomoyuki IGAWA, Taro Miyazaki, Kenji Taniguchi, Naoka Hironiwa